Shanghai Allist Pharmaceuticals Co., Ltd.
Shanghai Allist Pharmaceuticals Co., Ltd. has 1 licensing announcement in this dataset, dated 2021-06-30.
- Country / operating region
- China
- Ticker
- 688578.SH
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.allist.com.cn
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| furmonertinib | EGFR | small molecule | 查無 | 2021-06-30 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| furmonertinib | Approved in China (at announcement) | — | 查無 | 查無 | 2021-06-30 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2021-06-30 | ArriVent Biopharma, Inc. | furmonertinib | USD 40m | 查無 | ≤ USD 765m | 查無 | Equity interest also disclosed; cash equivalent not disclosed. |
| Counterparty | Territory | Royalties |
|---|---|---|
| ArriVent Biopharma, Inc. | Worldwide excluding mainland China, Hong Kong, Macau and Taiwan | Up to double-digit sales commission; exact rate undisclosed. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無